NewTimeSpace: SSY Group Limited(02005.HK) announced that its Bumetanide has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Bumetanide is a loop diuretic, mainly indicated for the treatment of edema associated with heart failure, renal dysfunction and hepatic dysfunction.
The key to GEO in financial marketing lies in "logical alignment." By leveraging Yoyi Link's GEOPlus across its three-layer architecture of information, data, and dissemination, official viewpoints are transformed into structured assets comprehensible to AI, thereby enhancing retrieval weight.
NewTimeSpace News,On March 12, Singapore-based investment group Trendlines announced that its portfolio company IBI Ag has successfully completed the Proof of Concept (POC) for its AI-powered de novo protein design platform for novel bioinsecticides.
NewTimeSpace: HBM Holdings Limited (02142.HK) announced that the Investigational New Drug (IND) application for HBM7575 (also known as SKB575), a long‑acting bispecific antibody targeting TSLP and an undisclosed target for the treatment of atopic dermatitis, has been approved by the National Medical Products Administration (NMPA) of China.
NewTimeSpace:SSY Group Limited (02005.HK) announced that it has obtained the drug production registration approval from the National Medical Products Administration (NMPA) for Calcium Levofolinate for Injection (25mg). The product is classified as a Class 3 chemical drug and is deemed to have passed the consistency evaluation. It is mainly used for the treatment of gastric cancer and colorectal cancer.
NewTimeSpace: Shanghai Henlius Biotech, Inc. (02696.HK) announced a voluntary announcement that the Phase 1 clinical trial application of HLX97, a self-developed KAT6A/B small-molecule inhibitor, for the treatment of advanced/metastatic solid tumors has been approved by the National Medical Products Administration (NMPA) of China. As of the date of this announcement, no similar products have been approved for marketing worldwide.
Innogen Pharmaceutical-B, which once claimed the title of "Oversubscription King" on the HKEX in 2025, has recently faced a sluggish capital market. As of the close on March 4, 2026, its share price stood at HK$22.28, with a cumulative drop of nearly 20% over the past three days—just a step away from its HK$18.68 offer price. The company’s total market value has shrunk by over HK$10 billion from its early post-listing high to approximately HK$10.18 billion. The company's R&D is highly dependent on a single GLP-1 mechanism. The much-anticipated "weight loss indication" is not expected to complete clinical trials until Q4 2026, with approval potentially pushed to 2027.
As the "first Data Agent stock on the HKEX," Xunce (03317.HK) has demonstrated strong share price performance since its listing at the end of 2025. As of March 3, 2026, the closing price was HK$77.45, up 61.35% from the offer price, and it was included in the Hang Seng Composite Index in just 45 days. However, the enthusiasm in the secondary market cannot hide its fundamental pressures. Core financial and operational warnings: revenue in the first half of 2025 decreased by 30% year-on-year, and the loss for the period expanded to RMB 108 million. R&D expenses remain high, consistently accounting for over 70% of revenue.
NewTimeSpace News,According to a disclosure from the Singapore Exchange on March 2, Japan’s Takeda and U.S.-based Protagonist jointly announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Rusfertide and granted it Priority Review status for the treatment of polycythemia vera in adults.
NewTimeSpace: SSY Group Limited (02005.HK) announced a voluntary announcement that the Group has obtained the Drug Production Registration Approval for Doxapram Hydrochloride Injection (5ml:100mg) from the National Medical Products Administration (NMPA) of China.The product is classified as a Category 3 chemical drug and is deemed to have passed the consistency evaluation. It is the first approval among domestic enterprises, mainly indicated for the treatment of respiratory failure.
In 2026, MINIMAX-WP (00100.HK) debuted on the Hong Kong stock market, with its market cap once surpassing HK$300 billion. As of February 27, its market cap was approximately **HK$239.5 billion**, nearly four times its offer price. However, based on the projected 2025 revenue of US$71 million, its **P/S ratio is a high 431x**, far exceeding OpenAI (~64x) and Anthropic (~81x), indicating a significant valuation premium. While revenue for the first three quarters of 2025 was US$53.44 million (up 175%), losses for the same period reached US$512 million, with cumulative losses since inception exceeding RMB 9 billion.
Cambridge Industries Group (06166.HK) conducted a secondary listing in Hong Kong in October 2025, with its shares soaring 33.86% on the first day due to strong Q3 results. However, the stock saw a significant correction entering 2026, with a year-to-date decline of 28.34% as of February 27, leaving the A/H premium at over 70%. Affected by an approximately RMB 81.61 million exchange loss and supply chain fluctuations, the company's Q4 2025 net profit decelerated sharply compared to the RMB 259 million earned in the first three quarters. Currently, the ongoing shortage of upstream optical chips (such as EML) remains the critical bottleneck restricting the release of its AI computing dividends.
NewTimeSpace News: SSY Group Limited (02005.HK) announced in a voluntary disclosure that its metoclopramide and metoclopramide hydrochloride have been approved by the National Medical Products Administration (NMPA) of China for registration as active pharmaceutical ingredients (APIs) for use in marketed finished dosage forms.
Since debuting on the HKEX in January 2026, Knowledge Atlas Tech’s market cap once soared to HK$320 billion, with its share price rising more than 524% from the offer price. Although its new flagship model GLM-5 demonstrates potential on par with top international models, the company’s recent public apology due to restricted service expansion has exposed weaknesses in operations and computing support. The company suffers from "insufficient self-sustenance," with cumulative R&D investment from 2022 to the first half of 2025 reaching RMB 4.4 billion against revenue of only RMB 685 million. Computing costs remain a heavy burden, with approximately 70% of R&D investment used for purchasing computing power.
PHANCY (06682.HK) has issued a clarification announcement regarding market rumors about the impact of AI large models on the software industry. It emphasizes that the company's main computing power business has precisely benefited from the development trend of AI large models. In the first three quarters of 2025, its revenue increased by 36.8% year-on-year and it achieved quarterly profitability for the first time. The board of directors confirms that business operations are normal and that it is not aware of any inside information that should be disclosed but has not been disclosed.
Since its listing in December 2025,Lemo(02539.HK), the "first stock of shared massage chairs," has seen its share price undergo violent fluctuations—first doubling and then being "halved" within two months—recording a single-day drop of nearly 40% in early February 2026. Although the company firmly holds the top spot in the industry with a 42.9% market share, its financial fundamentals are facing severe challenges. The automated massage service market has a limited size, and peers such as Rotai and Ogawa have already scaled back this business; nevertheless,Lemo continues to insist on using 60% of its raised funds for service point expansion.
